Why is a benefits investigation important?
Genentech BioOncology Access Solutions for ALECENSA conducts a
benefits investigation (BI) to help you better understand your
patient's health insurance plan coverage for the costs associated with
treatment. The BI can also determine if a prior authorization (PA) or
patient assistance might be needed.
There are 3 possible outcomes of a BI:
- Treatment is covered
- PA is required
- Treatment is denied
To begin with Genentech BioOncology Access Solutions, you must
complete and submit a Statement of Medical Necessity (SMN) form and
have your patient complete and submit a Patient Authorization and
Notice of Release of Information (PAN) form. To request a BI, be sure
to check the appropriate box on the SMN.
This description of a BI is for informational purposes only.
Genentech BioOncology Access Solutions makes no representation or
guarantee concerning reimbursement or coverage for any service or item.
Genentech BioOncology Access Solutions for ALECENSA can help your
practice identify if a prior authorization (PA) is needed and offer
support as you obtain it for your patient. All we need to begin are a
completed and signed Statement of Medical Necessity (SMN) form
requesting our assistance with the PA as well as a signed and dated
Patient Authorization and Notice of Release of Information (PAN)
Genentech BioOncology Access Solutions can help you as you submit the required PA forms and documentation. If the PA is not granted, Genentech BioOncology Access Solutions can work with you to determine your next steps. Tips like this can be found in Forms and Documents.
With the SureStart Program, eligible patients may receive treatment while awaiting an insurance coverage determination.
SureStart Program Eligibility
A patient should be eligible for the SureStart Program if the following conditions are met:
- Patient is taking ALECENSA for an approved indication
- Patient has not received a coverage decision within 7 days
If you think your patient qualifies for the SureStart Program, submit completed SMN and PAN forms to Genentech BioOncology Access Solutions.
Eligible patients can receive a 30-day supply of ALECENSA. Once coverage has been determined, the patient no longer qualifies for the SureStart Program.